Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;71(6):943-50.
doi: 10.1111/j.1365-2125.2010.03860.x.

Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age

E Fatma Sen  1 , Katia M C Verhamme, Mariagrazia Felisi, Geert W 't Jong, Carlo Giaquinto, Gino Picelli, Adriana Ceci, Miriam C J M Sturkenboom; TEDDY European Network of Excellence
Affiliations

Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age

E Fatma Sen et al. Br J Clin Pharmacol. 2011 Jun.

Abstract

What is already known about this subject: • Cough and cold medicines are frequently used in children to treat upper respiratory tract infections without solid proof of benefits. • Safety issues have been raised about the use of these drugs in young children. • In 2007 international warnings were issued advising against use of these drugs in young children.

What this study adds: • Cough and cold medicines prescribing by primary care physicians has not really been influenced by international warnings in the Netherlands, where no additional national warnings were made and only partially in Italy. • A concerted action should be taken in Europe to advise strongly against the OTC use and prescription of cough and cold medicines in young children.

Aim: The aim of the study was to assess the influence of national and international warnings on the prescription rates of cough and cold medicines (CCMs) in the youngest children (<2 years) in the Netherlands and Italy.

Methods: Analysis of outpatient electronic medical records of children <2 years in Italy and the Netherlands was carried out. Age and country specific prescription prevalence rates were calculated for the period 2005-08. Comparisons of prescription rates in 2005 (pre) and 2008 (post) warnings were done by means of a chi-square test.

Results: The cohort consisted of 99,176 children <2 years of age. After international warnings, overall prescription rates for CCMs decreased slightly from 83 to 77/1000 person years (P= 0.05) in Italy and increased in the Netherlands from 74 to 92/1000 children per year. Despite the international warnings, prescription rates for nasal sympathomimetics and opium alkaloids increased in the Netherlands (P < 0.01). In Italy a significant decrease in the prescription rates of opium alkaloids and other cough suppressants (P < 0.01) was observed, and also a significant reduction in use of combinations of nasal sympathomimetics.

Conclusion: Despite the international safety warnings and negative benefit-risk profiles, prescription rates of cough and cold medicines remain substantial and were hardly affected by the warnings, especially in the Netherlands where no warning was issued. The hazards of use of these medicines in young children should be explicitly stipulated by the European Medicines Agency and all national agencies, in order to increase awareness amongst physicians and caretakers and reduce heterogeneity across the EU.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prescription rates of cough and cold medicines by database and year with 95% confidence intervals. IPCI Dutch database, Pedianet Italian database. IPCI (formula image); IPCI 95% CI upper limit (formula image); IPCI 95% CI lower limit (formula image); Pedianet (formula image); Pedianet 95% CI upper limit (formula image); Pedianet 95% CI lower limit (formula image)
Figure 2
Figure 2
Prescription rates of cough and cold medicines by database and calendar month. IPCI Dutch database, Pedianet Italian database. IPCI (formula image); Pedianet (formula image)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sharfstein JM, North M, Serwint JR. Over the counter but no longer under the radar – pediatric cough and cold medications. N Engl J Med. 2007;357:2321–4. - PubMed
    1. FDA. FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age. 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051137.html (last accessed 3 October 2009)
    1. MHRA. Press release: better medicines for children's coughs and colds. 2009. Available at: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON038902 (last accessed 3 October 2009)
    1. Canada H. Health Canada Releases Decision on the Labelling of Cough and Cold Products for Children. 2008. Available at: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/2008_184-eng.php (last accessed 3 October 2009)
    1. NPR/Kaiser Family Foundation/Harvard School of Public Health. Children's OTC cold medicines: the public, and parents, weigh in 2007. Available at: http://www.kff.org/kaiserpolls/upload/7725.pdf (last accessed 5 October 2009)

Publication types